Drug
Ct204v Cd19 Cd20
Ct204v Cd19 Cd20: highest development phase Phase 1/2, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| CT204V-CD19 × CD20 NCT07932496 | Phase 1/2 | Relapsed or Refractory B-Cell Malignancies |
Latest
No recent events.
Follow Ct204v Cd19 Cd20 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.